Myeloid cutar sankarar bargo: Sabon Maganin Cigaba

A KYAUTA Kyauta 2 | eTurboNews | eTN

Ascentage Pharma, wani kamfani na biopharmaceutical na duniya wanda ke haɓaka sabbin hanyoyin kwantar da hankali don ciwon daji, na kullum hepatitis B (CHB), da cututtukan da suka shafi shekaru, da Innovent Biologics, Inc. ("Innovent"), wani kamfani na biopharmaceutical na duniya wanda ke tasowa, kerawa. kuma yana tallata magunguna masu inganci don maganin cututtukan daji, na rayuwa, autoimmune da sauran manyan cututtuka, tare da sanar da cewa ɗan takarar novel magani olverembatinib na Guangzhou HealthQuest Pharma Co., Ltd., Inc., wani kamfani na Ascentage Pharma, ya mallaki gaba ɗaya. Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) ta amince da ita don kula da tsofaffi marasa lafiya tare da tyrosine kinase inhibitor (TKI) mai jurewa lokaci mai tsanani na cutar sankarar bargo na myeloid (CML-CP) ko CML (CML-AP) mai sauri da ke ɗauke da T315I maye gurbi kamar yadda ingantaccen gwajin gwaji ya tabbatar (alamar da ba a yarda da ita ba a Amurka).

Ascentage Pharma ne suka samar da shi tare da tallafi daga babban shirin ganowa da kera magunguna na kasa, olverembatinib magani ne mai yuwuwa mafi inganci wanda Innovent da Ascentage Pharma za su hada kai a kasuwannin China, don amfanin karin marasa lafiya da su. iyalai. Kamar yadda BCL-ABL TKI na farko na ƙarni na uku na kasar Sin ya haɓaka don maganin CML mai jure wa TKI, wannan amincewar ta cike wani muhimmin gibi na jiyya a cikin T315I-mutant CML, kuma ya nuna babban ci gaba da ke nuna cewa Ascentage Pharma ya samu nasarar shiga matakin kasuwanci.

Wannan yarda ga olverembatinib ya dogara ne akan sakamako daga mahimman karatun Mataki na II guda biyu - binciken HQP1351CC201 da binciken HQP1351CC202. Wadannan sakamakon sun nuna cewa olverembatinib yana da tasiri kuma yana da kyau a cikin marasa lafiya tare da CML-CP da CML-AP, kuma ana sa ran yiwuwar da zurfin amsawar asibiti zai karu tare da tsawon lokaci na magani.

CML shine mummunan ciwon jini na farin jini. Gabatarwar BCR-ABL TKIs sun inganta ingantaccen kulawar asibiti na CML. Koyaya, juriya da aka samu ga TKIs ya kasance babban ƙalubale a cikin kula da CML. BCR-ABL tyrosine kinase maye gurbi yana wakiltar mahimmin hanyar da aka samu na juriya na miyagun ƙwayoyi; T315I, wanda shine maye gurbi na yau da kullun da ke jure muggan ƙwayoyi, yana faruwa a kusan kashi 25% na marasa lafiya tare da CML mai jurewar ƙwayoyi. Marasa lafiya tare da T315I-mutant CML suna da juriya ga masu hanawa na farko- da na biyu na BCR-ABL, don haka suna gabatar da buƙatar gaggawa ta likita don ingantaccen magani.

Game da marubucin

Avatar na Linda Hohnholz, editan eTN

Linda Hohnholz, editan eTN

Linda Hohnholz tana rubuce-rubuce da gyara labarai tun farkon fara aikinta. Ta yi amfani da wannan sha'awar a wurare kamar su Hawaii Pacific University, Chaminade University, da Hawaii's Discovery Center, da yanzu TravelNewsGroup.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...